EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)

Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, Rucsandra Dobrota, Mike Oliver Becker, Carina Mihai, Sinziana Muraru, Muriel Elhai, Suzana Jordan, Eric Hachulla, Ulf Müller-Ladner, Elise Siegert und 24 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2025.12.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Liubov Petelytska und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Internal Medicine n 3, Bogomolets Na…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Scleroderma, Systemic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Interstitial lung disease (ILD) carries significant morbidity and mortality risk in systemic sclerosis (SSc). We aimed to estimate the incidence of new-onset SSc-ILD and the associated risk factors, as well as its impact on the prognosis. METHODS: Patients classified as having SSc, with the absence of ILD signs on high-resolution computed tomography (HRCT) at baseline and having at least 1 follow-up visit with available HRCT data, were selected. SSc-ILD incidence was calculated as a rate per 100 person-years. Predictors of new-onset ILD and risk factors for ILD progression and mortality were chosen according to the literature and expert opinion. Risk factors for new-onset ILD, as well as its prognostic impact on ILD progression and mortality, were tested by generalised logistic estimating equation and Cox regression models, respectively. RESULTS: Among 5331 patients with SSc with negative baseline HRCT, the incidence of new-onset ILD was 3.83 cases per 100 person-years. Notably, there was a continuous detection of new ILD onset up to 10 years from baseline. Risk factors for new-onset ILD included New York Heart Association stage ≥2, muscle weakness, high inflammatory markers, and SSc-specific autoantibodies, but not disease duration. Despite a lower risk of ILD progression compared with prevalent ILD diagnosed at baseline, incident ILD still carried an increased risk for mortality, which was almost double when compared with ILD-negative cases. CONCLUSIONS: Patients with SSc should be considered for regular screening following a negative baseline HRCT, in particular when carrying high-risk features for new ILD onset, given its incidence and prognostic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialScleroderma, SystemicHumansFemalePrognosisIncidenceRisk FactorsMiddle AgedMaleDisease ProgressionTomography, X-Ray ComputedAdultAgedCohort Studies

Autor:innen und Institutionen

  • Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Internal Medicine n 3, Bogomolets National Medical University, Kyiv, Ukraine.
  • Department of Statistics Informatics & Applications, University of Florence, Florence, Italy.
  • Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Internal Medicine and Clinical Immunology, National Referral Centre for Rare Systemic Auto-immune and Auto-inflammatory Diseases, Inserm, CHU Lille, U1286 - INFINITE, University of Lille, Lille, France.
  • Department of Internal Medicine and Clinical Immunology, Justus-Liebig-University Giessen, Bad Nauheim, Germany.

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Petelytska, L., Tofani, L., Velauthapillai, A., Dobrota, R., Becker, M. O., Mihai, C., Muraru, S., Elhai, M., Jordan, S., Hachulla, E., Müller-Ladner, U., Siegert, E., Allanore, Y., Riemekasten, G., Bergmann, C., Becvar, R., Solanki, K., Anic, B., Szabo, I., …, & EUSTAR collaborators (2026). The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133). Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.12.008

Vancouver

Petelytska L, Tofani L, Velauthapillai A, Dobrota R, Becker MO, Mihai C, et al. The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133). Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.12.008

BibTeX
@article{Petelytska2026,
  author = {Petelytska, Liubov and Tofani, Lorenzo and Velauthapillai, Arthiha and Dobrota, Rucsandra and Becker, Mike Oliver and Mihai, Carina and Muraru, Sinziana and Elhai, Muriel and Jordan, Suzana and Hachulla, Eric and Müller-Ladner, Ulf and Siegert, Elise and Allanore, Yannick and Riemekasten, Gabriela and Bergmann, Christina and Becvar, Radim and Solanki, Kamal and Anic, Branimir and Szabo, Iulia and Stamenkovic, Bojana and Distler, Jörg and Carreira, Patricia E and Cuomo, Giovanna and Castellví, Ivan and Balbir-Gurman, Alexandra and Airò, Paolo and Litinsky, Ira and Saketkoo, Lesley Ann and Bertaccini, Bruno and Vonk, Madelon C and de Vries-Bouwstra, Jeska and Hoffmann-Vold, Anna-Maria and Matucci-Cerinic, Marco and Distler, Oliver and Bruni, Cosimo and EUSTAR collaborators, EUSTAR collaborators},
  title = {The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2025.12.008}
}
Kostenlos starten →